{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:06:49Z","timestamp":1791623209943,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd003277.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000}}],"reference-count":124,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003277.pub4","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T04:35:21Z","timestamp":1617770121000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Anti-seizure medications for Lennox-Gastaut syndrome"],"prefix":"10.1002","volume":"2022","author":[{"given":"Francesco","family":"Brigo","sequence":"additional","affiliation":[{"name":"Department of Neurology; Hospital of Merano (SABES-ASDAA); Merano-Meran Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Jones","sequence":"additional","affiliation":[{"name":"Cochrane Pain, Palliative and Supportive Care; Oxford University Hospitals NHS Foundation Trust; Oxford UK"},{"name":"Cochrane Pain, Palliative and Supportive Care; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin","family":"Eltze","sequence":"additional","affiliation":[{"name":"University College London; London UK"},{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Matricardi","sequence":"additional","affiliation":[{"name":"Department of Child Neuropsychiatry; Children\u2019s Hospital \u201cG. Salesi\u201d, Ospedali Riuniti Ancona; Ancona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD003277.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejpn.2018.09.010","article-title":"Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (\u22651 to <4 years old) with Lennox-Gastaut syndrome: final results from randomized study 303","volume":"23","author":"Arzimanoglou","year":"2019","journal-title":"European Journal of Paediatric Neurology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003277.pub4-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/dmcn.13623","article-title":"Safety and cognitive development effects of rufinamide in paediatric patients with Lennox-Gastaut syndrome (LGS): study 303 final results","volume":"59","author":"Arzimanoglou","year":"2017","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"3","key":"10.1002\/14651858.CD003277.pub4-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"393-402","DOI":"10.1016\/j.ejpn.2015.12.015","article-title":"Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study","volume":"20","author":"Arzimanoglou","year":"2016","journal-title":"European Journal of Paediatric Neurology"},{"issue":"2","key":"10.1002\/14651858.CD003277.pub4-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"275-80","DOI":"10.1002\/epi4.12314","article-title":"Novel seizure outcomes in patients with Lennox-Gastaut syndrome: post hoc analysis of seizure-free days in rufinamide Study 303","volume":"4","author":"Auvin","year":"2019","journal-title":"Epilepsia Open"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003277.pub4-BIB0005|cit5","first-page":"Abstract no: P1","article-title":"Post hoc analysis of rufinamide study 303: seizure-free days in patients with Lennox-Gastaut Syndrome (LGS)","volume":"90","author":"Auvin","year":"2018","journal-title":"Neurology"},{"issue":"20","key":"10.1002\/14651858.CD003277.pub4-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD003277.pub4-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1212\/wnl.0000000000004380","article-title":"Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE3)","volume":"89","author":"Patel","year":"2017","journal-title":"Neurology"},{"issue":"S21","key":"10.1002\/14651858.CD003277.pub4-BIB0008|cit8","first-page":"S279","article-title":"Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox Gastaut Syndrome (LGS): results of a dose ranging, multicenter, randomized, double blind, placebo controlled trial (GWPCARE3)","volume":"82","author":"Wirrell","year":"2017","journal-title":"Annals of Neurology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003277.pub4-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1111\/epi.13944","article-title":"Cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut syndrome (LGS): results of a dose-ranging, multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE3)","volume":"58","author":"Zuberi","year":"2017","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003277.pub4-BIB0010|cit10","first-page":"S110","article-title":"Double-blind cross-over study with lamotrigine in children with Lennox-Gastaut syndrome and other types of generalized intractable epilepsy","volume":"36","author":"Eriksson","year":"1995","journal-title":"Epilepsia"},{"issue":"5","key":"10.1002\/14651858.CD003277.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1528-1157.1998.tb01411.x","article-title":"The efficacy of lamotrigine in children and adolescents with refractory generalised epilepsy: a randomised, double blind, crossover study","volume":"39","author":"Eriksson","year":"1998","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD003277.pub4-BIB0012|cit12","first-page":"S18","article-title":"Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial","volume":"34","author":"Dodson","year":"1993","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD003277.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJM199301073280105","article-title":"Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome)","volume":"328","author":"Felbamate Study Group in Lennox Gastaut syndrome","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003277.pub4-BIB0014|cit14","first-page":"619","article-title":"Felbamate for the treatment of Lennox-Gastaut syndrome","volume":"31","author":"Garofalo","year":"1990","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003277.pub4-BIB0015|cit15","first-page":"13","article-title":"A double-blind trial of felbamate in Lennox-Gastaut syndrome","volume":"32","author":"Ritter","year":"1991","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD003277.pub4-BIB0016|cit16","first-page":"156, abstract n","article-title":"Effects of rufinamide on the frequency of different seizure types in patients with Lennox-Gastaut syndrome: a long-term study","volume":"48","author":"Glauser","year":"2007","journal-title":"Epilepsia"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD003277.pub4-BIB0017|cit17","first-page":"408, abstract n","article-title":"Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome","volume":"46","author":"Glauser","year":"2005","journal-title":"Epilepsia"},{"issue":"21","key":"10.1002\/14651858.CD003277.pub4-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","article-title":"Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome","volume":"70","author":"Glauser","year":"2008","journal-title":"Neurology"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD003277.pub4-BIB0019|cit19","first-page":"S92, abstract n","article-title":"Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome","volume":"58","author":"Glauser","year":"2005","journal-title":"Annals of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD003277.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1826, abstract","DOI":"10.1212\/WNL.64.10.1826","article-title":"Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial","volume":"64","author":"Glauser","year":"2005","journal-title":"Neurology"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD003277.pub4-BIB0021|cit21","first-page":"261, abstract n","article-title":"Early and sustained response to rufinamide as adjunctive therapy for seizures associated with Lennox Gastaut syndrome","volume":"50","author":"Glauser","year":"2009","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD003277.pub4-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1600-0404.2010.01334.x","article-title":"Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study","volume":"122","author":"Kluger","year":"2010","journal-title":"Acta Neurologica Scandinavica"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003277.pub4-BIB0023|cit23","first-page":"139, abstract n","article-title":"Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome","volume":"47","author":"Kluger","year":"2006","journal-title":"Epilepsia"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD003277.pub4-BIB0024|cit24","first-page":"359, abstract n","article-title":"Long-term safety of rufinamide in patients with Lennox-Gastaut syndrome","volume":"48","author":"Krauss","year":"2007","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD003277.pub4-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40120-016-0041-9","article-title":"Treatment of adults with Lennox-Gastaut syndrome: further analysis of efficacy and safety\/tolerability of rufinamide","volume":"5","author":"McMurray","year":"2016","journal-title":"Neurology & Therapy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003277.pub4-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"211, Abstract n","DOI":"10.1111\/epi.13241","article-title":"Rufinamide as adjunctive treatment for adults with Lennox-Gastaut syndrome: subgroup analysis from a phase III trial","volume":"56","author":"Striano","year":"2015","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD003277.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1528-1157.1989.tb05321.x","article-title":"Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome","volume":"30","author":"Group for the Evaluation of Cinromide in the Lennox-Gastaut syndrome","year":"1989","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003277.pub4-BIB0028|cit28","first-page":"92","article-title":"Double-blind, placebo-controlled evaluation of the safety and efficacy of lamotrigine (Lamictal) for the treatment of patients with a clinical diagnosis of Lennox-Gastaut syndrome","volume":"37","author":"Billard","year":"1996","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD003277.pub4-BIB0029|cit29","first-page":"A109","article-title":"Clinician and caregiver assessments of global response to therapy strongly agree in a double-blind, placebo-controlled trial of lamotrigine in the Lennox-Gastaut syndrome","volume":"48","author":"Gallagher","year":"1997","journal-title":"Neurology"},{"issue":"25","key":"10.1002\/14651858.CD003277.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJM199712183372504","article-title":"Lamotrigine for generalised seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group","volume":"337","author":"Motte","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003277.pub4-BIB0031|cit31","first-page":"163, abstract n","article-title":"Improved neurological function accompanies effective control of the Lennox-Gastaut syndrome with Lamictal: results of a multinational, placebo-controlled trial","volume":"37","author":"Mullens","year":"1996","journal-title":"Epilepsia"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003277.pub4-BIB0032|cit32","first-page":"202, abstract n","article-title":"Safety and tolerability of adjunctive Lamictal\u00ae for the treatment of the Lennox-Gastaut syndrome: results of a multinational, double-blind, placebo-controlled trial","volume":"37","author":"Trevathan","year":"1996","journal-title":"Epilepsia"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD003277.pub4-BIB0033|cit33","first-page":"Abstract no: P4","article-title":"Combination AED treatment with clobazam in patients with Lennox\u2013Gastaut syndrome: post hoc analyses of the CONTAIN study","volume":"90","author":"Chung","year":"2018","journal-title":"Neurology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD003277.pub4-BIB0034|cit34","first-page":"360","article-title":"Safety and efficacy of clobazam, a novel 1,5-benzodiazepine, in the treatment of Lennox-Gastaut syndrome","volume":"48","author":"Conry","year":"2007","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0035|cit35","unstructured":"Conry J Ng Y Drummond R Stolle J Sagar S Efficacy and safety of clobazam in the treatment of seizures associated with Lennox Gastaut syndrome: results of a phase III trial 64th Annual Meeting of the American Epilepsy Society; 2010 December 3-7; San Antonio, TX www.aesnet.org\/go\/publications\/aes-abstracts\/abstract-search\/mode\/display\/st\/clobazam\/sy\/2010\/sb\/All\/id\/ Abstract no: 1.283"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003277.pub4-BIB0036|cit36","first-page":"391","article-title":"Efficacy and safety of clobazam for LGS patients who completed all 15 weeks of the phase III CONTAIN trial","volume":"14","author":"Conry","year":"2014","journal-title":"Epilepsy Currents"},{"issue":"S15","key":"10.1002\/14651858.CD003277.pub4-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"S113, Abstract","DOI":"10.1002\/ana.22572","article-title":"Efficacy and safety of clobazam for seizures associated with Lennox-Gastaut syndrome (LGS): results of a phase III study","volume":"70","author":"Conry","year":"2011","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD003277.pub4-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1111\/epi.13388","article-title":"Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012","volume":"57","author":"Isojarvi","year":"2016","journal-title":"Epilepsia"},{"issue":"Suppl 17","key":"10.1002\/14651858.CD003277.pub4-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"S75, Abstract n","DOI":"10.1002\/ana.24068","article-title":"Somnolence and sedation were transient AES for most patients receiving clobazam during a phase III study in Lennox-Gastaut syndrome (LGS)","volume":"74","author":"Isojarvi","year":"2013","journal-title":"Annals of Neurology"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD003277.pub4-BIB0040|cit40","first-page":"Abstract no: P0","article-title":"Response to clobazam in relationship to baseline seizure frequency","volume":"80","author":"Isojarvi","year":"2013","journal-title":"Neurology"},{"issue":"Suppl 17","key":"10.1002\/14651858.CD003277.pub4-BIB0041|cit41","first-page":"S72, Abstract n","article-title":"Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam","volume":"74","author":"Lee","year":"2013","journal-title":"Annals of Neurology"},{"issue":"15","key":"10.1002\/14651858.CD003277.pub4-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1212\/WNL.0b013e318232de76","article-title":"Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome","volume":"77","author":"Ng","year":"2011","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003277.pub4-BIB0043|cit43","first-page":"266","article-title":"Aggression in LGS patients treated with clobazam during the CONTAIN trial","volume":"13","author":"Paolicchi","year":"2013","journal-title":"Epilepsy Currents"},{"issue":"4","key":"10.1002\/14651858.CD003277.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.pediatrneurol.2015.06.021","article-title":"Clobazam and aggression-related adverse events in pediatric patients with Lennox-Gastaut syndrome","volume":"53","author":"Paolicchi","year":"2015","journal-title":"Pediatric Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003277.pub4-BIB0045|cit45","first-page":"392, Abstract n","article-title":"Response to clobazam among benzodiazepine-experienced LGS patients during the CONTAIN trial","volume":"14","author":"Rosenfeld","year":"2014","journal-title":"Epilepsy Currents"},{"issue":"7 Suppl","key":"10.1002\/14651858.CD003277.pub4-BIB0046|cit46","first-page":"Abstract no: P0","article-title":"Use of rescue medications by Lennox-Gastaut (LGS) patients treated with clobazam during the CONTAIN trial","volume":"80","author":"Rosenfeld","year":"2013","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD003277.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.eplepsyres.2014.08.019","article-title":"Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan","volume":"108","author":"Ohtsuka","year":"2014","journal-title":"Epilepsy Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003277.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1111\/j.1528-1157.2000.tb02179.x","article-title":"Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group","volume":"41","author":"Glauser","year":"2000","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003277.pub4-BIB0049|cit49","first-page":"131","article-title":"A double-blind trial of topiramate in Lennox-Gastaut syndrome (LGS)","volume":"38","author":"Glauser","year":"1997","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003277.pub4-BIB0050|cit50","first-page":"2","article-title":"Long-term experience with topiramate in Lennox-Gastaut syndrome","volume":"39","author":"Ritter","year":"1998","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003277.pub4-BIB0051|cit51","first-page":"94","article-title":"Topiramate as open-label adjunctive therapy in Lennox-Gastaut syndrome","volume":"38","author":"Ritter","year":"1997","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD003277.pub4-BIB0052|cit52","first-page":"37","article-title":"Open-label treatment of Lennox-Gastaut syndrome with topiramate","volume":"38","author":"Ritter","year":"1997","journal-title":"Epilepsia"},{"issue":"9","key":"10.1002\/14651858.CD003277.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1212\/WNL.52.9.1882","article-title":"A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group","volume":"52","author":"Sachdeo","year":"1999","journal-title":"Neurology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003277.pub4-BIB0054|cit54","first-page":"112, abstract n","article-title":"An open label evaluation of topiramate in Lennox-Gastaut syndrome","volume":"37","author":"Sachdeo","year":"1996","journal-title":"Epilepsia"},{"issue":"16 Suppl","key":"10.1002\/14651858.CD003277.pub4-BIB0055|cit55","first-page":"Abstract no: S2","article-title":"Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4)","volume":"88","author":"French","year":"2017","journal-title":"Neurology"},{"issue":"S21","key":"10.1002\/14651858.CD003277.pub4-BIB0056|cit56","first-page":"S293, Abstract","article-title":"Treatment with cannabidiol (CBD) significantly reduces drop and total seizure frequency in Lennox-Gastaut Syndrome (LGS): results of a multicenter, randomized, double-blind, placebo controlled trial (GWPCARE4)","volume":"82","author":"Joshi","year":"2017","journal-title":"Annals of Neurology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003277.pub4-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"S55, Abstract n","DOI":"10.1111\/epi.13944","article-title":"Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-centre, randomised, double-blind, placebo-controlled trial (GWPCARE4)","volume":"58","author":"Mazurkiewicz-Beldzinska","year":"2017","journal-title":"Epilepsia"},{"issue":"10125","key":"10.1002\/14651858.CD003277.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003277.pub4-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s13311-017-0543-x","article-title":"Treatment with cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox Gastaut Syndrome (LGS): results of a multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE4)","volume":"14","author":"Thiele","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1002\/14651858.CD003277.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0387-7604(12)80052-0","article-title":"Double-blind placebo-controlled trial of flunarizine as add-on therapy in refractory childhood epilepsy","volume":"13","author":"Battaglia","year":"1991","journal-title":"Brain and Development"},{"issue":"5","key":"10.1002\/14651858.CD003277.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1528-1167.2008.01935.x","article-title":"Clobazam in the treatment of Lennox-Gastaut syndrome","volume":"50","author":"Conry","year":"2009","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD003277.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1528-1157.1989.tb05323.x","article-title":"Clinical study of oral administration of DN-1417, a TRH analog, in patients with intractable epilepsy","volume":"30","author":"Inanaga","year":"1989","journal-title":"Epilepsia"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003277.pub4-BIB0063|cit63","first-page":"155, Abstract n","article-title":"The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome","volume":"37","author":"Oletsky","year":"1996","journal-title":"Epilepsia"},{"issue":"2","key":"10.1002\/14651858.CD003277.pub4-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/1535759719835671","article-title":"Don't fear the reefer - evidence mounts for plant-based cannabidiol as treatment for epilepsy","volume":"19","author":"Perry","year":"2019","journal-title":"Epilepsy Currents"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0065|cit65","first-page":"177","article-title":"Clinical experience with clobazam: a new 1,5 benzodiazepine in the treatment of refractory epilepsy","volume":"21","author":"Vajda","year":"1985","journal-title":"Clinical and Experimental Neurology"},{"issue":"19","key":"10.1002\/14651858.CD003277.pub4-BIB0066|cit66","first-page":"713","article-title":"Double-blind study on the anticonvulsive effect of phenobarbital and valproate in the Lennox syndrome","volume":"108","author":"Vassella","year":"1978","journal-title":"Schweizerische Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0067|cit67","unstructured":"Vigevano F Cilio MR Antonini L Clinical experience with Felbamate in paediatric age Bollettino - Lega Italiana Contro L'Epilessia 1994 63 6 10.1016\/s0920-1211(01)00290-x"},{"issue":"4","key":"10.1002\/14651858.CD003277.pub4-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3805\/jjes.25.425","article-title":"Single-blind and controlled comparative study of lamotrigine with zonisamide for refractory pediatric epilepsy","volume":"25","author":"Ohtahara","year":"2008","journal-title":"Journal of the Japan Epilepsy Society"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0069|cit69","unstructured":"A comparative, randomized, open label, multicentric, prospective clinical study to evaluate the efficacy, safety and tolerability of rufinamide tablet vs. lamotrigine (adjunctive therapy) in the treatment of seizures associated with Lennox-Gastaut syndrome http:\/\/www.ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=2237 2011"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0070|cit70","unstructured":"Phase III randomized, double-blind, placebo-controlled study of oral topiramate for Lennox-Gastaut syndrome http:\/\/ClinicalTrials.gov\/show\/NCT00004776 1993"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0071|cit71","unstructured":"Melatonin versus placebo in the Lennox-Gastaut syndrome: neurophysiological and neuropsychological effects http:\/\/ClinicalTrials.gov\/show\/NCT01370486 2011"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0072|cit72","unstructured":"Cannabidiol oral solution as an adjunctive therapy for treatment of subjects with inadequately controlled Lennox-Gastaut syndrome https:\/\/ClinicalTrials.gov\/show\/NCT02318537 2016"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0073|cit73","unstructured":"A study to investigate the efficacy and safety of ZX008 (fenfluramine hydrochloride) as an adjunctive therapy in children and adults with Lennox-Gastaut syndrome https:\/\/clinicaltrials.gov\/show\/NCT03355209"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0074|cit74","unstructured":"A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of TAK-935 (OV935) as an adjunctive therapy in pediatric patients with developmental and\/or epileptic encephalopathies https:\/\/ClinicalTrials.gov\/show\/NCT03650452 2018"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0075|cit75","unstructured":"Cannabis extract in refractory epilepsy study https:\/\/clinicaltrials.gov\/show\/NCT03808935 2019"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003277.pub4-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1111\/epi.13944","article-title":"Design and methods of study 338: a multicenter, double-blind, randomized, placebo-controlled trial of perampanel as adjunctive treatment in subjects >=2 years of age with inadequately controlled seizures associated with Lennox-Gastaut syndrome","volume":"58","author":"Wechsler","year":"2017","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003277.pub4-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/dmcn.13623","article-title":"Design and methods of study 338: a multicentre, double-blind, randomised, placebo-controlled trial of perampanel as adjunctive treatment in patients >=2 years of age with inadequately controlled seizures associated with Lennox-Gastaut syndrome","volume":"59","author":"Wechsler","year":"2017","journal-title":"Developmental Medicine and Child Neurology"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0078|cit78","volume-title":"Manual for the Child Behavior Checklist\/4\u201318 and 1991 Profile. Department of Psychiatry","author":"Achenbach","year":"1991"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"104822","DOI":"10.1016\/j.phrs.2020.104822","article-title":"Cannabis sativa: much more beyond \u0394 9-tetrahydrocannabinol","volume":"157","author":"Alves","year":"2020","journal-title":"Pharmacological Research"},{"issue":"1","key":"10.1002\/14651858.CD003277.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1474-4422(08)70292-8","article-title":"Lennox Gastaut syndrome: a consensus approach on diagnosis, assessment, management and trial methodology","volume":"8","author":"Arzimanoglou","year":"2009","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD003277.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10072-017-3188-y","article-title":"Lennox-Gastaut syndrome: a comprehensive review","volume":"39","author":"Asadi-Pooya","year":"2018","journal-title":"Neurological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD003277.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/0883073809348355","article-title":"Increased risk of death among children with Lennox-Gastaut syndrome and infantile spasms","volume":"25","author":"Autry","year":"2010","journal-title":"Journal of Child Neurology"},{"issue":"3","key":"10.1002\/14651858.CD003277.pub4-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2165\/11313640-000000000-00000","article-title":"The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK","volume":"28","author":"Benedict","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1002\/14651858.CD003277.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1528-1157.1999.tb00739.x","article-title":"Newly diagnosed epilepsy in children: presentation at diagnosis","volume":"40","author":"Berg","year":"1999","journal-title":"Epilepsia"},{"issue":"11","key":"10.1002\/14651858.CD003277.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/epi.14569","article-title":"Evolution and course of early life developmental encephalopathic epilepsies: focus on Lennox-Gastaut syndrome","volume":"59","author":"Berg","year":"2018","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD003277.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s13760-019-01185-5","article-title":"Therapeutic approach to Lennox-Gastaut syndrome: a systematic review","volume":"119","author":"Borrelli","year":"2019","journal-title":"Acta Neurololgica Belgica"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0087|cit87","volume-title":"NeuroPsychopharmacotherapy","author":"Brigo","year":"2021"},{"issue":"3","key":"10.1002\/14651858.CD003277.pub4-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/epi.16438","article-title":"Biological concepts in human sodium channel epilepsies and their relevance in clinical practice","volume":"61","author":"Brunklaus","year":"2020","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD003277.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1528-1157.1998.tb01382.x","article-title":"Familial occurrence of epilepsy in children with newly diagnosed multiple seizures: Dutch Study of Epilepsy in Childhood","volume":"39","author":"Callenbach","year":"1998","journal-title":"Epilepsia"},{"issue":"2","key":"10.1002\/14651858.CD003277.pub4-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/ane.12086","article-title":"Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome","volume":"128","author":"Cramer","year":"2013","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0091|cit91","volume-title":"Epileptic Syndromes in Infancy, Childhood and Adolescence","author":"Crespel","year":"2019"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3389\/fneur.2017.00505","article-title":"Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations","volume":"8","author":"Cross","year":"2017","journal-title":"Frontiers in Neurology"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0093|cit93","unstructured":"Deeks JJ Higgins JPT Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eplepsyres.2018.09.011","article-title":"Diagnosis switching and outcomes in a cohort of patients with potential epilepsy with myoclonic-atonic seizures","volume":"147","author":"Eschbach","year":"2018","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0095|cit95","unstructured":"The European Parliament and the Council of the European Union Regulation (EC) No 1901\/2006 of the European Council and of the Council of 12th December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768\/92, Directive 2001\/20\/EC, Directive 2001\/83\/EC and Regulation (EC) No 726\/2004 www.emea.europa.eu\/htms\/human\/paediatrics\/regulation.htm 2006"},{"issue":"2-3","key":"10.1002\/14651858.CD003277.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.eplepsyres.2010.01.012","article-title":"Lennox-Gastaut syndrome in adulthood: clinical and EEG features","volume":"89","author":"Ferlazzo","year":"2010","journal-title":"Epilepsy Research"},{"issue":"8","key":"10.1002\/14651858.CD003277.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1212\/01.WNL.0000123693.82339.FC","article-title":"Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0098|cit98","unstructured":"Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0099|cit99","unstructured":"Higgins JP Eldridge S Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD003277.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy","volume":"30","author":"International League Against Epilepsy","year":"1989","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0101|cit101","unstructured":"International League Against Epilepsy Lennox Gastaut syndrome https:\/\/www.epilepsydiagnosis.org\/syndrome\/lgs-overview.html"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD003277.pub4-BIB0102|cit102","first-page":"S54","article-title":"Felbamate in the treatment of Lennox-Gastaut syndrome","volume":"35","author":"Jensen","year":"1994","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD003277.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0920-1211(99)00021-2","article-title":"Delineation of cryptogenic Lennox-Gastaut syndrome and myoclonic astatic epilepsy using multiple correspondence analysis","volume":"36","author":"Kaminska","year":"1999","journal-title":"Epilepsy Research"},{"issue":"2","key":"10.1002\/14651858.CD003277.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1212\/WNL.0000000000005756","article-title":"Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society","volume":"91","author":"Kanner","year":"2018","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD003277.pub4-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40263-018-0558-9","article-title":"Efficacy and safety of adjunctive cannabidiol in patients with Lennox-Gastaut syndrome: a systematic review and meta-analysis","volume":"32","author":"Lattanzi","year":"2018","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1002\/14651858.CD003277.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1090\u20138","DOI":"10.1111\/epi.16546","article-title":"Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis","volume":"61","author":"Lattanzi","year":"2020","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0107|cit107","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0108|cit108","unstructured":"National Institute for Health and Care Excellence (NICE) Epilepsies: diagnosis and management. Clinical guideline [CG137] Available from: https:\/\/www.nice.org.uk\/guidance\/cg137 (accessed 19\/02\/2021)"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0109|cit109","unstructured":"National Institute for Health and Care Excellence (NICE) Cannabidiol with clobazam for treating seizures associated with Lennox\u2013Gastaut syndrome. Technology appraisal guidance [TA615] Available from: https:\/\/www.nice.org.uk\/guidance\/ta615 (accessed 19\/02\/2021)"},{"issue":"4","key":"10.1002\/14651858.CD003277.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.pediatrneurol.2015.06.021","article-title":"Clobazam and aggression-related adverse events in pediatric patients with Lennox-Gastaut syndrome","volume":"53","author":"Paolicchi","year":"2015","journal-title":"Pediatric Neurology"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.yebeh.2017.05.021","article-title":"Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome","volume":"73","author":"Pi\u00f1a-Garza","year":"2017","journal-title":"Epilepsy & Behavior"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0112|cit112","unstructured":"Review Manager 5 (RevMan 5) Cochrane 2020"},{"issue":"5","key":"10.1002\/14651858.CD003277.pub4-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"a022780","DOI":"10.1101\/cshperspect.a022780","article-title":"Mechanisms of action of antiseizure drugs and the ketogenic diet","volume":"6","author":"Rogawski","year":"2016","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0114|cit114","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JPT Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0115|cit115","doi-asserted-by":"crossref","DOI":"10.1002\/9781444325201","volume-title":"Handbook of Epilepsy Treatment","author":"Shorvon","year":"2010"},{"issue":"5","key":"10.1002\/14651858.CD003277.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/CPJ.0000000000000527","article-title":"Late-onset Lennox-Gastaut syndrome: diagnostic evaluation and outcome","volume":"8","author":"Smith","year":"2018","journal-title":"Neurology. Clinical Practice"},{"issue":"12","key":"10.1002\/14651858.CD003277.pub4-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/j.1528-1157.1997.tb00065.x","article-title":"Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children","volume":"38","author":"Trevathan","year":"1997","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0118|cit118","volume-title":"Treatment of epilepsies","author":"Trinka","year":"2015"},{"key":"10.1002\/14651858.CD003277.pub4-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yebeh.2017.09.006","article-title":"Lennox-Gastaut syndrome in adulthood: long-term clinical follow-up of 38 patients and analysis of their recorded seizures","volume":"77","author":"Vignoli","year":"2017","journal-title":"Epilepsy & Behavior"},{"issue":"1-2","key":"10.1002\/14651858.CD003277.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eplepsyres.2011.03.009","article-title":"Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: a population-based study","volume":"95","author":"Wirrell","year":"2011","journal-title":"Epilepsy Research"},{"issue":"5","key":"10.1002\/14651858.CD003277.pub4-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/brain\/awx054","article-title":"Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders","volume":"140","author":"Wolff","year":"2017","journal-title":"Brain"},{"issue":"3","key":"10.1002\/14651858.CD003277.pub4-BIB0122|cit122","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003277","article-title":"Treatment of Lennox-Gastaut syndrome","author":"Cross","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD003277.pub4-BIB0123|cit123","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003277.pub2","article-title":"Treatment of Lennox-Gastaut syndrome","author":"Cross","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003277.pub4-BIB0124|cit124","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003277.pub3","article-title":"Treatment of Lennox-Gastaut syndrome","author":"Hancock","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:02:41Z","timestamp":1789344161000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003277.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":124,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003277.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]}}}